搜索
名称描述内容
BAY 11-7082 (NF-κB抑制剂)
0.00
0.00
商品描述
BAY 11-7082是一种常用的NF-κB抑制剂。BAY 11-7082可以抑制一些细胞因子诱导的IκBα的磷酸化，从而抑制IκBα降解和随后的NF-κB核转运，最终抑制依赖于NF-κB的基因转录。
BAY 11-7082分子量为207.25，分子式为C10H9NO2S。本产品纯度大于99%。
本BAY 11-7082为进口分装，其中20mg/ml包装产品用DMSO配制，共0.1ml。10mg和50mg包装为粉末装。
包装清单：
| 产品编号 | 产品名称 | 包装 |
| S1523-2mg | BAY 11-7082 (NF-κB抑制剂) | 20mg/ml×0.1ml |
| S1523-10mg | BAY 11-7082 (NF-κB抑制剂) | 10mg |
| S1523-50mg | BAY 11-7082 (NF-κB抑制剂) | 50mg |
| — | 说明书 | 1份 |
保存条件：
-20℃避光保存，一年有效。
注意事项：
本BAY 11-7082在4℃、冰浴等较低温度情况下会凝固而粘在离心管管底、管壁或管盖内，可以20-25℃水浴温育片刻至全部融解后使用。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
1. BAY 11-7082常见使用浓度范围为1-100μM。具体的最佳工作浓度请参考相关文献，或根据实验目的，以及所培养的特定细胞和组织，通过实验进行摸索和优化。
相关产品：
NF-κB Signaling：
NF-κB Signaling：
| 产品编号 | 产品名称 | 产品包装 |
| S1523-2mg | BAY 11-7082 (NF-κB抑制剂) | 20mg/ml×0.1ml |
| S1523-10mg | BAY 11-7082 (NF-κB抑制剂) | 10mg |
| S1523-50mg | BAY 11-7082 (NF-κB抑制剂) | 50mg |
| S1732-0.5mg | LPS (TLR4激活剂) | 2mg/ml×0.25ml |
| S1732-5mg | LPS (TLR4激活剂) | 5mg |
| S1732-25mg | LPS (TLR4激活剂) | 25mg |
| S1735 | LPS (Ultrapure, TLR4激活剂) | 5mg/ml×0.1ml |
| S1771 | NS-398 (COX-2抑制剂) | 1mg |
| S1772 | NS-398 (COX-2抑制剂) | 5mg |
| S1808 | PDTC (NF-κB抑制剂/抗氧化剂) | 1g |
| S1809 | PDTC (NF-κB抑制剂/抗氧化剂) | 5g |
| SC0299-10mM | Curcumin (COX抑制剂) | 10mM×0.2ml |
| SC0299-5mg | Curcumin (COX抑制剂) | 5mg |
| SC0299-25mg | Curcumin (COX抑制剂) | 25mg |
| SD0006-10mM | PD123319 (RAAS抑制剂) | 10mM |
| SD0006-5mg | PD123319 (RAAS抑制剂) | 5mg |
| SD0006-25mg | PD123319 (RAAS抑制剂) | 25mg |
| SD0015-10mM | LCZ696 (RAAS抑制剂) | 10mM |
| SD0015-5mg | LCZ696 (RAAS抑制剂) | 5mg |
| SD0015-25mg | LCZ696 (RAAS抑制剂) | 25mg |
| SD0024-10mM | Azilsartan (RAAS拮抗剂) | 10mM |
| SD0024-5mg | Azilsartan (RAAS拮抗剂) | 5mg |
| SD0024-25mg | Azilsartan (RAAS拮抗剂) | 25mg |
| SD7212-10mM | Avasimibe (P450抑制剂) | 10mM |
| SD7212-5mg | Avasimibe (P450抑制剂) | 5mg |
| SD7212-25mg | Avasimibe (P450抑制剂) | 25mg |
| SF0002-10mM | WS3 (IκB/IKK抑制剂) | 10mM |
| SF0002-5mg | WS3 (IκB/IKK抑制剂) | 5mg |
| SF0002-25mg | WS3 (IκB/IKK抑制剂) | 25mg |
| SF0006-10mM | WS6 (IκB/IKK抑制剂) | 10mM |
| SF0006-5mg | WS6 (IκB/IKK抑制剂) | 5mg |
| SF0006-25mg | WS6 (IκB/IKK抑制剂) | 25mg |
| SF0011-10mM | BAY11-7082 (IκB/IKK抑制剂) | 10mM |
| SF0011-5mg | BAY11-7082 (IκB/IKK抑制剂) | 5mg |
| SF0011-25mg | BAY11-7082 (IκB/IKK抑制剂) | 25mg |
| SF0020-10mM | BAY 11-7085 (IκB/IKK抑制剂) | 10mM |
| SF0020-5mg | BAY 11-7085 (IκB/IKK抑制剂) | 5mg |
| SF0020-25mg | BAY 11-7085 (IκB/IKK抑制剂) | 25mg |
| SF0024-10mM | Bardoxolone Methyl (IκB/IKK抑制剂) | 10mM |
| SF0024-5mg | Bardoxolone Methyl (IκB/IKK抑制剂) | 5mg |
| SF0024-25mg | Bardoxolone Methyl (IκB/IKK抑制剂) | 25mg |
| SF0029-10mM | SC-514 (IκB/IKK抑制剂) | 10mM |
| SF0029-5mg | SC-514 (IκB/IKK抑制剂) | 5mg |
| SF0029-25mg | SC-514 (IκB/IKK抑制剂) | 25mg |
| S1748-1mg | MG-132 (Proteasome抑制剂) | 20mg/ml×0.05ml |
| S1748-25mg | MG-132 (Proteasome抑制剂) | 25mg |
| S1748-5mg | MG-132 (Proteasome抑制剂) | 5mg |
| SC0078-10mM | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 10mM×0.2ml |
| SC0078-25mg | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 25mg |
| SC0078-5mg | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 5mg |
| SC0083-10mM | MLN9708 (20S proteasome抑制剂) | 10mM×0.2ml |
| SC0083-25mg | MLN9708 (20S proteasome抑制剂) | 25mg |
| SC0083-5mg | MLN9708 (20S proteasome抑制剂) | 5mg |
| SC0263-10mM | Bortzeomib (PS-341) (Proteasome抑制剂) | 10mM×0.2ml |
| SC0263-25mg | Bortzeomib (PS-341) (Proteasome抑制剂) | 25mg |
| SC0263-5mg | Bortzeomib (PS-341) (Proteasome抑制剂) | 5mg |
| SD7198-10mM | Epoxomicin (20S Proteasome抑制剂) | 10mM |
| SD7198-25mg | Epoxomicin (20S Proteasome抑制剂) | 25mg |
| SD7198-5mg | Epoxomicin (20S Proteasome抑制剂) | 5mg |
| SF4157-10mM | Carfilzomib (proteasome抑制剂) | 10mM |
| SF4157-25mg | Carfilzomib (proteasome抑制剂) | 25mg |
| SF4157-5mg | Carfilzomib (proteasome抑制剂) | 5mg |
| 产品编号 | 产品名称 | 产品包装 |
| S1523-2mg | BAY 11-7082 (NF-κB抑制剂) | 20mg/ml×0.1ml |
| S1523-10mg | BAY 11-7082 (NF-κB抑制剂) | 10mg |
| S1523-50mg | BAY 11-7082 (NF-κB抑制剂) | 50mg |
| S1732-0.5mg | LPS (TLR4激活剂) | 2mg/ml×0.25ml |
| S1732-5mg | LPS (TLR4激活剂) | 5mg |
| S1732-25mg | LPS (TLR4激活剂) | 25mg |
| S1735 | LPS (Ultrapure, TLR4激活剂) | 5mg/ml×0.1ml |
| S1771 | NS-398 (COX-2抑制剂) | 1mg |
| S1772 | NS-398 (COX-2抑制剂) | 5mg |
| S1808 | PDTC (NF-κB抑制剂/抗氧化剂) | 1g |
| S1809 | PDTC (NF-κB抑制剂/抗氧化剂) | 5g |
| SC0299-10mM | Curcumin (COX抑制剂) | 10mM×0.2ml |
| SC0299-5mg | Curcumin (COX抑制剂) | 5mg |
| SC0299-25mg | Curcumin (COX抑制剂) | 25mg |
| SD0006-10mM | PD123319 (RAAS抑制剂) | 10mM |
| SD0006-5mg | PD123319 (RAAS抑制剂) | 5mg |
| SD0006-25mg | PD123319 (RAAS抑制剂) | 25mg |
| SD0015-10mM | LCZ696 (RAAS抑制剂) | 10mM |
| SD0015-5mg | LCZ696 (RAAS抑制剂) | 5mg |
| SD0015-25mg | LCZ696 (RAAS抑制剂) | 25mg |
| SD0024-10mM | Azilsartan (RAAS拮抗剂) | 10mM |
| SD0024-5mg | Azilsartan (RAAS拮抗剂) | 5mg |
| SD0024-25mg | Azilsartan (RAAS拮抗剂) | 25mg |
| SD7212-10mM | Avasimibe (P450抑制剂) | 10mM |
| SD7212-5mg | Avasimibe (P450抑制剂) | 5mg |
| SD7212-25mg | Avasimibe (P450抑制剂) | 25mg |
| SF0002-10mM | WS3 (IκB/IKK抑制剂) | 10mM |
| SF0002-5mg | WS3 (IκB/IKK抑制剂) | 5mg |
| SF0002-25mg | WS3 (IκB/IKK抑制剂) | 25mg |
| SF0006-10mM | WS6 (IκB/IKK抑制剂) | 10mM |
| SF0006-5mg | WS6 (IκB/IKK抑制剂) | 5mg |
| SF0006-25mg | WS6 (IκB/IKK抑制剂) | 25mg |
| SF0011-10mM | BAY11-7082 (IκB/IKK抑制剂) | 10mM |
| SF0011-5mg | BAY11-7082 (IκB/IKK抑制剂) | 5mg |
| SF0011-25mg | BAY11-7082 (IκB/IKK抑制剂) | 25mg |
| SF0020-10mM | BAY 11-7085 (IκB/IKK抑制剂) | 10mM |
| SF0020-5mg | BAY 11-7085 (IκB/IKK抑制剂) | 5mg |
| SF0020-25mg | BAY 11-7085 (IκB/IKK抑制剂) | 25mg |
| SF0024-10mM | Bardoxolone Methyl (IκB/IKK抑制剂) | 10mM |
| SF0024-5mg | Bardoxolone Methyl (IκB/IKK抑制剂) | 5mg |
| SF0024-25mg | Bardoxolone Methyl (IκB/IKK抑制剂) | 25mg |
| SF0029-10mM | SC-514 (IκB/IKK抑制剂) | 10mM |
| SF0029-5mg | SC-514 (IκB/IKK抑制剂) | 5mg |
| SF0029-25mg | SC-514 (IκB/IKK抑制剂) | 25mg |
| S1748-1mg | MG-132 (Proteasome抑制剂) | 20mg/ml×0.05ml |
| S1748-25mg | MG-132 (Proteasome抑制剂) | 25mg |
| S1748-5mg | MG-132 (Proteasome抑制剂) | 5mg |
| SC0078-10mM | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 10mM×0.2ml |
| SC0078-25mg | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 25mg |
| SC0078-5mg | Ixazeomib (MLN2238) (20S proteasome抑制剂) | 5mg |
| SC0083-10mM | MLN9708 (20S proteasome抑制剂) | 10mM×0.2ml |
| SC0083-25mg | MLN9708 (20S proteasome抑制剂) | 25mg |
| SC0083-5mg | MLN9708 (20S proteasome抑制剂) | 5mg |
| SC0263-10mM | Bortzeomib (PS-341) (Proteasome抑制剂) | 10mM×0.2ml |
| SC0263-25mg | Bortzeomib (PS-341) (Proteasome抑制剂) | 25mg |
| SC0263-5mg | Bortzeomib (PS-341) (Proteasome抑制剂) | 5mg |
| SD7198-10mM | Epoxomicin (20S Proteasome抑制剂) | 10mM |
| SD7198-25mg | Epoxomicin (20S Proteasome抑制剂) | 25mg |
| SD7198-5mg | Epoxomicin (20S Proteasome抑制剂) | 5mg |
| SF4157-10mM | Carfilzomib (proteasome抑制剂) | 10mM |
| SF4157-25mg | Carfilzomib (proteasome抑制剂) | 25mg |
| SF4157-5mg | Carfilzomib (proteasome抑制剂) | 5mg |
|
产品编号
|
产品名称
|
产品包装
|
|
S1523-2mg
|
BAY 11-7082
(NF-κB抑制剂)
|
20mg/ml×0.1ml
|
|
S1523-10mg
|
BAY 11-7082
(NF-κB抑制剂)
|
10mg
|
|
S1523-50mg
|
BAY 11-7082
(NF-κB抑制剂)
|
50mg
|
|
S1732-0.5mg
|
LPS (TLR4激活剂)
|
2mg/ml×0.25ml
|
|
S1732-5mg
|
LPS (TLR4激活剂)
|
5mg
|
|
S1732-25mg
|
LPS (TLR4激活剂)
|
25mg
|
|
S1735
|
LPS (Ultrapure,
TLR4激活剂)
|
5mg/ml×0.1ml
|
|
S1771
|
NS-398 (COX-2抑制剂)
|
1mg
|
|
S1772
|
NS-398 (COX-2抑制剂)
|
5mg
|
|
S1808
|
PDTC (NF-κB抑制剂/抗氧化剂)
|
1g
|
|
S1809
|
PDTC (NF-κB抑制剂/抗氧化剂)
|
5g
|
|
SC0299-10mM
|
Curcumin (COX抑制剂)
|
10mM×0.2ml
|
|
SC0299-5mg
|
Curcumin (COX抑制剂)
|
5mg
|
|
SC0299-25mg
|
Curcumin (COX抑制剂)
|
25mg
|
|
SD0006-10mM
|
PD123319 (RAAS抑制剂)
|
10mM
|
|
SD0006-5mg
|
PD123319 (RAAS抑制剂)
|
5mg
|
|
SD0006-25mg
|
PD123319 (RAAS抑制剂)
|
25mg
|
|
SD0015-10mM
|
LCZ696 (RAAS抑制剂)
|
10mM
|
|
SD0015-5mg
|
LCZ696 (RAAS抑制剂)
|
5mg
|
|
SD0015-25mg
|
LCZ696 (RAAS抑制剂)
|
25mg
|
|
SD0024-10mM
|
Azilsartan (RAAS拮抗剂)
|
10mM
|
|
SD0024-5mg
|
Azilsartan (RAAS拮抗剂)
|
5mg
|
|
SD0024-25mg
|
Azilsartan (RAAS拮抗剂)
|
25mg
|
|
SD7212-10mM
|
Avasimibe (P450抑制剂)
|
10mM
|
|
SD7212-5mg
|
Avasimibe (P450抑制剂)
|
5mg
|
|
SD7212-25mg
|
Avasimibe (P450抑制剂)
|
25mg
|
|
SF0002-10mM
|
WS3 (IκB/IKK抑制剂)
|
10mM
|
|
SF0002-5mg
|
WS3 (IκB/IKK抑制剂)
|
5mg
|
|
SF0002-25mg
|
WS3 (IκB/IKK抑制剂)
|
25mg
|
|
SF0006-10mM
|
WS6 (IκB/IKK抑制剂)
|
10mM
|
|
SF0006-5mg
|
WS6 (IκB/IKK抑制剂)
|
5mg
|
|
SF0006-25mg
|
WS6 (IκB/IKK抑制剂)
|
25mg
|
|
SF0011-10mM
|
BAY11-7082
(IκB/IKK抑制剂)
|
10mM
|
|
SF0011-5mg
|
BAY11-7082
(IκB/IKK抑制剂)
|
5mg
|
|
SF0011-25mg
|
BAY11-7082
(IκB/IKK抑制剂)
|
25mg
|
|
SF0020-10mM
|
BAY 11-7085
(IκB/IKK抑制剂)
|
10mM
|
|
SF0020-5mg
|
BAY 11-7085
(IκB/IKK抑制剂)
|
5mg
|
|
SF0020-25mg
|
BAY 11-7085
(IκB/IKK抑制剂)
|
25mg
|
|
SF0024-10mM
|
Bardoxolone Methyl
(IκB/IKK抑制剂)
|
10mM
|
|
SF0024-5mg
|
Bardoxolone Methyl
(IκB/IKK抑制剂)
|
5mg
|
|
SF0024-25mg
|
Bardoxolone Methyl
(IκB/IKK抑制剂)
|
25mg
|
|
SF0029-10mM
|
SC-514 (IκB/IKK抑制剂)
|
10mM
|
|
SF0029-5mg
|
SC-514 (IκB/IKK抑制剂)
|
5mg
|
|
SF0029-25mg
|
SC-514 (IκB/IKK抑制剂)
|
25mg
|
|
S1748-1mg
|
MG-132
(Proteasome抑制剂)
|
20mg/ml×0.05ml
|
|
S1748-25mg
|
MG-132
(Proteasome抑制剂)
|
25mg
|
|
S1748-5mg
|
MG-132
(Proteasome抑制剂)
|
5mg
|
|
SC0078-10mM
|
Ixazeomib (MLN2238)
(20S proteasome抑制剂)
|
10mM×0.2ml
|
|
SC0078-25mg
|
Ixazeomib (MLN2238)
(20S proteasome抑制剂)
|
25mg
|
|
SC0078-5mg
|
Ixazeomib (MLN2238)
(20S proteasome抑制剂)
|
5mg
|
|
SC0083-10mM
|
MLN9708 (20S
proteasome抑制剂)
|
10mM×0.2ml
|
|
SC0083-25mg
|
MLN9708 (20S
proteasome抑制剂)
|
25mg
|
|
SC0083-5mg
|
MLN9708 (20S
proteasome抑制剂)
|
5mg
|
|
SC0263-10mM
|
Bortzeomib (PS-341)
(Proteasome抑制剂)
|
10mM×0.2ml
|
|
SC0263-25mg
|
Bortzeomib (PS-341)
(Proteasome抑制剂)
|
25mg
|
|
SC0263-5mg
|
Bortzeomib (PS-341)
(Proteasome抑制剂)
|
5mg
|
|
SD7198-10mM
|
Epoxomicin (20S
Proteasome抑制剂)
|
10mM
|
|
SD7198-25mg
|
Epoxomicin (20S
Proteasome抑制剂)
|
25mg
|
|
SD7198-5mg
|
Epoxomicin (20S
Proteasome抑制剂)
|
5mg
|
|
SF4157-10mM
|
Carfilzomib
(proteasome抑制剂)
|
10mM
|
|
SF4157-25mg
|
Carfilzomib
(proteasome抑制剂)
|
25mg
|
|
SF4157-5mg
|
Carfilzomib
(proteasome抑制剂)
|
5mg
|
联系微信
用户至上，用心服务
联系QQ
联系地址：广州市海珠区新滘中路161号广骏商务中心423室（地铁：3号线大塘站）
电话：020-80929345
传真：020-80929345
电话：020-80929345
传真：020-80929345
020-80929345
Sale Hotline
联系我们
友情链接